Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.58 |
| ▸ | CLPP | Q16740 | 13/20 | 0.56 |
| ▸ | STARD3 | Q14849 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | CBFB | Q13951 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435800 | 0.90 | CLPP (0.68) | CLPPMEN1KMT2A | |
| SCHEMBL3053501 | 0.85 | SLC6A5 (0.58) | SLC6A5CLPPSTARD3PARP1TNKS2 | |
| SCHEMBL14107496 | 0.84 | SLC6A5 (0.57) | SLC6A5CLPPSTARD3PARP1TNKS2 | |
| SCHEMBL5226852 | 0.84 | SLC6A5 (0.57) | SLC6A5CLPPSTARD3PARP1TNKS2 | |
| SCHEMBL4871477 | 0.82 | GAA (0.57) | SLC6A5CLPPSTARD3PARP1TNKS2 | |
| SCHEMBL4864912 | 0.81 | SLC6A5 (0.54) | SLC6A5CLPPSTARD3PARP1TNKS2 | |
| SCHEMBL14086093 | 0.80 | SLC6A5 (0.53) | SLC6A5CLPPSTARD3PARP1TNKS2 | |
| SCHEMBL29888556 | 0.78 | KMT2A (0.55) | SLC6A5CLPPPARP1TNKS2PARP2 | |
| SCHEMBL10036330 | 0.78 | KMT2A (0.55) | SLC6A5CLPPPARP1TNKS2PARP2 | |
| SCHEMBL1550311 | 0.77 | KDM4E (0.63) | SLC6A5CLPPSTARD3PARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20050209261-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-22 | — | — | US | disclosed |
| US-6943172-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050192304-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-01 | — | — | US | disclosed |
| US-6924290-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20040002507-A1 | Rho-kinase inhibitors | BAYER CORPORATION (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002507-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | SLC6A5 4630/4885CLPP 4205/4885STARD3 2488/4885 |
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | SLC6A5 4630/4885CLPP 4205/4885STARD3 2488/4885 |
| US-20050209261-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | SLC6A5 4630/4885CLPP 4205/4885STARD3 2488/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | SLC6A5 4199/4885CLPP 4514/4885STARD3 2577/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | SLC6A5 4630/4885CLPP 4205/4885STARD3 2488/4885 |
| US-20050192304-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | SLC6A5 4630/4885CLPP 4205/4885STARD3 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.